Coherus BioSciences Past Earnings Performance
Past criteria checks 0/6
Coherus BioSciences's earnings have been declining at an average annual rate of -33.5%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been declining at an average rate of 11.9% per year.
Key information
-33.5%
Earnings growth rate
-32.6%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -11.9% |
| Return on equity | n/a |
| Net Margin | -0.1% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Investors Don't See Light At End Of Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Tunnel And Push Stock Down 30%
Nov 06
Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 27% Dive
Sep 22Evaluating Coherus BioSciences: Udenyca's Success And Loqtorzi's Prospects
Aug 13Why Investors Shouldn't Be Surprised By Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Low P/S
Aug 07Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway
May 31Shareholders May Be More Conservative With Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation For Now
May 23Coherus Biosciences: Dumping One Drug But Showing Promise With Another
Mar 21Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 29% Dive
Feb 03Coherus BioSciences: FDA Approvals Spice Up The Pipeline
Jan 17Investors Aren't Buying Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Revenues
Dec 20The Consensus EPS Estimates For Coherus BioSciences, Inc. (NASDAQ:CHRS) Just Fell Dramatically
May 13Coherus to launch its biosimilar to Roche's eye disorder drug Lucentis in U.S. on Oct. 3
Sep 19Coherus: 2022 Is In Many Ways A Make Or Break Year
Aug 24Coherus stock soars 14% on FDA nod for Roche Lucentis' interchangeable biosimilar Cimerli
Aug 03Coherus, Shanghai Junshi refiling for toripalimab gets FDA review in rare head/neck cancer
Jul 06Would Coherus BioSciences (NASDAQ:CHRS) Be Better Off With Less Debt?
Jun 15Coherus: Will Its Chinese Gambit Fail?
May 27Revenue & Expenses Breakdown
How Coherus BioSciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 304 | 0 | 163 | 95 |
| 30 Jun 24 | 308 | -29 | 172 | 102 |
| 31 Mar 24 | 302 | -59 | 186 | 100 |
| 31 Dec 23 | 257 | -238 | 186 | 106 |
| 30 Sep 23 | 211 | -217 | 192 | 112 |
| 30 Jun 23 | 182 | -264 | 193 | 129 |
| 31 Mar 23 | 183 | -271 | 195 | 151 |
| 31 Dec 22 | 211 | -292 | 198 | 199 |
| 30 Sep 22 | 239 | -279 | 195 | 221 |
| 30 Jun 22 | 276 | -230 | 190 | 229 |
| 31 Mar 22 | 304 | -210 | 179 | 246 |
| 31 Dec 21 | 327 | -287 | 170 | 363 |
| 30 Sep 21 | 364 | -232 | 157 | 357 |
| 30 Jun 21 | 395 | -165 | 149 | 342 |
| 31 Mar 21 | 443 | -76 | 143 | 310 |
| 31 Dec 20 | 476 | 132 | 139 | 143 |
| 30 Sep 20 | 489 | 162 | 137 | 192 |
| 30 Jun 20 | 487 | 181 | 137 | 153 |
| 31 Mar 20 | 435 | 145 | 140 | 127 |
| 31 Dec 19 | 356 | 90 | 137 | 94 |
| 30 Sep 19 | 232 | -12 | 135 | 0 |
| 30 Jun 19 | 121 | -118 | 128 | 0 |
| 31 Mar 19 | 37 | -185 | 110 | 0 |
| 31 Dec 18 | 0 | -209 | 94 | 106 |
| 30 Sep 18 | 0 | -196 | 75 | 0 |
| 30 Jun 18 | 0 | -196 | 64 | 0 |
| 31 Mar 18 | 1 | -208 | 67 | 0 |
| 31 Dec 17 | 2 | -238 | 69 | 0 |
| 30 Sep 17 | 2 | -265 | 69 | 0 |
| 30 Jun 17 | 165 | -122 | 69 | 0 |
| 31 Mar 17 | 178 | -137 | 59 | 0 |
| 31 Dec 16 | 190 | -127 | 52 | 0 |
| 30 Sep 16 | 199 | -104 | 47 | 0 |
| 30 Jun 16 | 44 | -259 | 44 | 0 |
| 31 Mar 16 | 37 | -248 | 41 | 0 |
| 31 Dec 15 | 30 | -223 | 36 | 0 |
| 30 Sep 15 | 26 | -200 | 30 | 0 |
| 30 Jun 15 | 35 | -137 | 24 | 0 |
| 31 Mar 15 | 33 | -103 | 19 | 0 |
| 31 Dec 14 | 31 | -87 | 16 | 0 |
| 30 Sep 14 | 26 | -73 | 14 | 0 |
| 30 Jun 14 | 10 | -86 | 12 | 0 |
| 31 Mar 14 | 6 | -70 | 10 | 0 |
| 31 Dec 13 | 3 | -54 | 7 | 0 |
Quality Earnings: CHRS is currently unprofitable.
Growing Profit Margin: CHRS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CHRS is unprofitable, and losses have increased over the past 5 years at a rate of 33.5% per year.
Accelerating Growth: Unable to compare CHRS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CHRS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: CHRS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.